“We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world,” sabi ni Moderna CEO Stephane Bancel sa isang statement na inilabas sa pamamagitan ng Philippine News Agency (PNA).

Naghahanda na para sa global launching ng kanilang vaccine na mRNA-1273 laban sa COVID-19 ang American biotechnology company na Moderna, ayon sa balitang ilabas ng Xinhua, araw ng Biyernes.

“We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world,” sabi ni Moderna CEO Stephane Bancel sa isang statement na inilabas sa pamamagitan ng Philippine News Agency (PNA).

Dagdag sa Phase 3 study ng COVID-19 vaccine na mRNA-1273 na fully enrolled, ang Moderna ay mayroon nang apat na programa sa Phase 2 studies, ayon kay Bancel.

“Moderna is committed to the highest data quality standards and rigorous scientific research as we continue to work with regulators to advance mRNA-1273,” sabi niya.

Noong October 22, ay nakumpleto ng Phase 3 study ang pag-e-enrol ng may 30,000 partisipante na may 37 percent mula sa diverse communities.

Ang Phase 1 interim analysis ng vaccine na na-publish sa The New England Journal of Medicine noong July 14 ay nagpapakita na ang mRNA-1273 ay “well-tolerated” sa lahat ng age groups at nag-induce ng rapid at strong immune response laban sa SARS-CoV-2.

Write a comment
Follow by Email
LinkedIn
Share